What is Halozyme Therapeutics, Inc.'s Market Cap?

Halozyme Therapeutics, Inc.'s Market Cap is $12.0B, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Enterprise Value?

Halozyme Therapeutics, Inc.'s Enterprise Value is $14.0B, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Trailing P/E?

Halozyme Therapeutics, Inc.'s Trailing P/E is 29.1×, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Price / Sales?

Halozyme Therapeutics, Inc.'s Price / Sales is 7.2×, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s EV / Revenue?

Halozyme Therapeutics, Inc.'s EV / Revenue is 8.4×, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s EV / EBITDA?

Halozyme Therapeutics, Inc.'s EV / EBITDA is 23.3×, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Revenue (TTM)?

Halozyme Therapeutics, Inc.'s Revenue (TTM) is $1.7B, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Net Income (TTM)?

Halozyme Therapeutics, Inc.'s Net Income (TTM) is $413.6M, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s EBITDA?

Halozyme Therapeutics, Inc.'s EBITDA is $611.8M, based on as-reported figures from SEC (XBRL) filings.

What is Halozyme Therapeutics, Inc.'s Diluted EPS (TTM)?

Halozyme Therapeutics, Inc.'s Diluted EPS (TTM) is 3.64, based on as-reported figures from SEC (XBRL) filings.

Halozyme Therapeutics, Inc. (HALO) Financial Statements

Halozyme Therapeutics, Inc.

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG001SGX585

XNAS · usd

106.03▼ 2.28 (-2.11%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value

Trailing P/E

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close108.31

Day's Range106.07 – 109.96

52-Week Range61.23 – 111.15

Volume1.6M

Avg Volume2.1M

Share Statistics

Shares Outstanding

Employees423

ExchangeXNAS

Listed2004-03-12

Share count as of July 31, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Halozyme Therapeutics, Inc. (HALO)

What is Halozyme Therapeutics, Inc.'s Market Cap?: Halozyme Therapeutics, Inc.'s Market Cap is $12.0B, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Enterprise Value?: Halozyme Therapeutics, Inc.'s Enterprise Value is $14.0B, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Trailing P/E?: Halozyme Therapeutics, Inc.'s Trailing P/E is 29.1×, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Price / Sales?: Halozyme Therapeutics, Inc.'s Price / Sales is 7.2×, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s EV / Revenue?: Halozyme Therapeutics, Inc.'s EV / Revenue is 8.4×, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s EV / EBITDA?: Halozyme Therapeutics, Inc.'s EV / EBITDA is 23.3×, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Revenue (TTM)?: Halozyme Therapeutics, Inc.'s Revenue (TTM) is $1.7B, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Net Income (TTM)?: Halozyme Therapeutics, Inc.'s Net Income (TTM) is $413.6M, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s EBITDA?: Halozyme Therapeutics, Inc.'s EBITDA is $611.8M, based on as-reported figures from SEC (XBRL) filings.
What is Halozyme Therapeutics, Inc.'s Diluted EPS (TTM)?: Halozyme Therapeutics, Inc.'s Diluted EPS (TTM) is 3.64, based on as-reported figures from SEC (XBRL) filings.